GB1310658A - Composition and method for treatment of hepatic disease and mental fatugue - Google Patents

Composition and method for treatment of hepatic disease and mental fatugue

Info

Publication number
GB1310658A
GB1310658A GB4677271A GB4677271A GB1310658A GB 1310658 A GB1310658 A GB 1310658A GB 4677271 A GB4677271 A GB 4677271A GB 4677271 A GB4677271 A GB 4677271A GB 1310658 A GB1310658 A GB 1310658A
Authority
GB
United Kingdom
Prior art keywords
composition
hepatic disease
mental
fatugue
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4677271A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richardson Merrell SpA
Original Assignee
Richardson Merrell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Merrell SpA filed Critical Richardson Merrell SpA
Publication of GB1310658A publication Critical patent/GB1310658A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1310658 Pharmaceutical composition RICHARDSON-MERRELL SpA 7 Oct 1971 [15 Oct 1970] 46772/71 Heading A5B A composition for treating hepatic disease and mental fatigue and promoting urea synthesis in the liver comprises (a) L-argenine or a salt thereof (3 parts by weight), (b) L- ornithine or a salt thereof (1-2 parts by weight) and (c) a carrier. The composition may also include as active ingredients: methionine, lipoic acid, cocarboxylase, coenzyme B 12 , coenzyme A, liver extract or oxybetaine. It may be administered intravenously, intramuscularly or orally.
GB4677271A 1970-10-15 1971-10-07 Composition and method for treatment of hepatic disease and mental fatugue Expired GB1310658A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8093670A 1970-10-15 1970-10-15

Publications (1)

Publication Number Publication Date
GB1310658A true GB1310658A (en) 1973-03-21

Family

ID=22160611

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4677271A Expired GB1310658A (en) 1970-10-15 1971-10-07 Composition and method for treatment of hepatic disease and mental fatugue

Country Status (9)

Country Link
AU (1) AU3460571A (en)
BE (1) BE773910A (en)
DE (1) DE2150900A1 (en)
FR (1) FR2110465A1 (en)
GB (1) GB1310658A (en)
IL (1) IL37904A0 (en)
NL (1) NL7114199A (en)
PH (1) PH12920A (en)
ZA (1) ZA716628B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2199243A (en) * 1986-09-17 1988-07-06 Natural Vitality Ltd Pharmaceutical compositions comprising ornithine and arginine
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
EP1252892A1 (en) * 2001-04-25 2002-10-30 Ito En, Ltd. Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor
WO2003099238A1 (en) * 2002-05-29 2003-12-04 Unilever Plc Odor control in amine salt containing cosmetic compositions
US7932288B2 (en) 2005-10-04 2011-04-26 Kyowa Hakko Bio Co., Ltd. Composition for relieving subjective symptoms of fatigue
US8173706B2 (en) 2009-04-03 2012-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US8389576B2 (en) 2004-11-26 2013-03-05 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
US11266620B2 (en) 2009-06-08 2022-03-08 Ucl Business Ltd Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059775B1 (en) * 1980-06-09 1984-09-19 Leopold & Co. Chem. pharm. Fabrik Gesellschaft m.b.H. Infusion solution for the protection of the liver and the improvement of its functioning, and process for its production
ATE70974T1 (en) * 1987-12-04 1992-01-15 Asta Pharma Ag INJECTABLE SOLUTION OF THIOCT ACID SALT WITH TROMETAMOLE AND/OR BASIC AMINO ACIDS.
IE67874B1 (en) * 1989-11-09 1996-05-01 Asta Medica Ag Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses
FR2791571B1 (en) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic ASSOCIATION OF NO SYNTHASE INHIBITOR (S) AND METABOLIC ANTIOXIDANT (S)
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US20100137226A1 (en) * 2006-06-07 2010-06-03 Kyowa Hakko Bio Co., Ltd Fatigue-reducing agent
JP5623916B2 (en) 2008-01-31 2014-11-12 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ Pharmaceutical composition for aneurysmal subarachnoid hemorrhage and vasospasm

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2199243A (en) * 1986-09-17 1988-07-06 Natural Vitality Ltd Pharmaceutical compositions comprising ornithine and arginine
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
WO2001056402A3 (en) * 2000-02-01 2002-08-22 Muscletech Res And Dev Inc Alpha lipoic acid based food supplement to increase lean muscle mass and strength
EP1252892A1 (en) * 2001-04-25 2002-10-30 Ito En, Ltd. Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor
WO2003099238A1 (en) * 2002-05-29 2003-12-04 Unilever Plc Odor control in amine salt containing cosmetic compositions
US10610506B2 (en) 2004-11-26 2020-04-07 Ucl Business Ltd Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US8389576B2 (en) 2004-11-26 2013-03-05 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US9566257B2 (en) 2004-11-26 2017-02-14 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US7932288B2 (en) 2005-10-04 2011-04-26 Kyowa Hakko Bio Co., Ltd. Composition for relieving subjective symptoms of fatigue
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions
US9034925B2 (en) 2009-04-03 2015-05-19 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US10173964B2 (en) 2009-04-03 2019-01-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US8785498B2 (en) 2009-04-03 2014-07-22 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US11161802B2 (en) 2009-04-03 2021-11-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US8492439B2 (en) 2009-04-03 2013-07-23 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US9604909B2 (en) 2009-04-03 2017-03-28 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US8173706B2 (en) 2009-04-03 2012-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US10550069B2 (en) 2009-04-03 2020-02-04 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US11266620B2 (en) 2009-06-08 2022-03-08 Ucl Business Ltd Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
US9260379B2 (en) 2010-10-06 2016-02-16 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
US10525029B2 (en) 2014-11-24 2020-01-07 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
US11040021B2 (en) 2014-11-24 2021-06-22 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate

Also Published As

Publication number Publication date
PH12920A (en) 1979-10-10
NL7114199A (en) 1972-04-18
FR2110465A1 (en) 1972-06-02
AU3460571A (en) 1973-04-19
IL37904A0 (en) 1971-12-29
ZA716628B (en) 1972-06-28
DE2150900A1 (en) 1972-04-20
BE773910A (en) 1972-01-31

Similar Documents

Publication Publication Date Title
GB1310658A (en) Composition and method for treatment of hepatic disease and mental fatugue
KR840003414A (en) Pharmaceutical compositions containing 3-hydroxybutanoic acid or salts derived from these acids, and compounds derived from 3-hydroxybutanoic acid that can be used as pharmaceuticals
NL7509249A (en) PROCESS FOR THE PREPARATION OF NEW 5,9- (BETA) -DI- SUBSTITUTED 2-TETRA-HYDROFURFURYL-6,7-BENZOMORPHANS AND THEIR ACID ADDITION SALTS, PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONTAINING THE STANDARDS CONTAINED AS WELL AS FORMED PHARMACEUTICAL PREPARATIONS OBTAINED BY THE LATEST METHOD.
GB1388358A (en) Taste-improving formulations of oral penicillins
GB1411149A (en) Blood lipid level-controlling and anti-coagulant drugs
EG10508A (en) Method for preparation of 5-aryl 2,3-dihydro-2,2(or 3,3)dimethyl-5h-imidazo(2,1-a)isoindol-5-ols and 2(4,4(5,5)dimethyl-2-imidazolin-2-yl)bensophenone acid addition salts used as autidepressant drug
GB1256723A (en)
GB1018117A (en)
IE35419L (en) Pharmaceutical composition containing cyclobenzaprine
NL7504717A (en) PROCESS FOR THE PREPARATION OF L-LYSINE ENRICHED YEASTS WHICH CAN FORM CITRIC ACID, ISOCITROIC ACID AND GLUTAMIC ACID ON FERMENT.
IE35711L (en) Pharmaceutical compositions
IE33519B1 (en) Novel benzyl-hydrazide derivatives and a process for the manufacture thereof and novel benzylidene-hydrazide derivatives useful in said process
GB1420976A (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
GB1352392A (en) Phenylisopropylamine derivatives
IE33520B1 (en) Novel benzyl-hydrazide derivatives and a process for the manufacture thereof and novel benzylidene-hydrazide derivatives useful in said process
GB1357813A (en) Effervescent composition for the treatment of heart diseases
Weingartner et al. DOM (STP), a new hallucinogenic drug: specific perceptual changes.
NL154419B (en) PROCESS FOR THE PREPARATION OF MEDICINAL PRODUCTS CONTAINING (BETA-PHENYLSULFINYLETHYL) -N, N'-DIPHENYL-MALONIC ACID MONOHYDRAZIDE AND / OR ONE OR MORE PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF.
GB1394397A (en) Chlorphenesin derivatives and method of making same
GB1178984A (en) Improvements in or relating to Hepatic Medicines
GB1472086A (en) Pharmaceutical composition for treatment of liver diseases
GB1127405A (en) Pharmaceutical composition for the treatment of parkinson syndrome
JPS57179118A (en) Antitumor agent
IE38235B1 (en) Preparations for combatting swine dysentery
IE32617L (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PLNP Patent lapsed through nonpayment of renewal fees